Last updated: February 21, 2026
What does patent BR112016015909 cover?
Brazilian patent BR112016015909, filed by Astellas Pharma Inc. and granted on November 24, 2016, protects a pharmaceutical invention targeting novel aminopyrimidine derivatives. These compounds exhibit inhibitory activity against specific kinase enzymes, specifically Src family kinases and Lck tyrosine kinases, which are involved in cancer cell proliferation and immune responses.
The patent claims cover:
- The chemical scope of the specific aminopyrimidine compounds, including various substitutions on the core structure.
- Pharmaceutical compositions containing these compounds.
- Methods for treating diseases associated with kinase activity, notably oncology and autoimmune disorders.
The patent aims to secure exclusivity over both the molecules and their use as kinase inhibitors.
What are the primary claims?
The main claims focus on:
- Chemical compounds: Structural formulas with defined core and variable groups, emphasizing substitutions that optimize kinase inhibition.
- Methods of use: Administration of the compounds for conditions related to abnormal kinase activity, such as cancer, rheumatoid arthritis, and other autoimmune diseases.
- Pharmaceutical compositions: Formulations incorporating the compounds, including tablets, capsules, and injectables.
Claim structures include:
- Independent claims for the compounds themselves.
- Dependent claims specifying substituent details.
- Use claims addressing treatment methods.
Patent scope analysis
The scope centers on aminopyrimidine derivatives with kinase inhibition activity, with detailed claims covering:
- Chemical heterogeneity: Variations in substituents R1, R2, R3, R4, etc., allowing broad coverage of compounds sharing core features.
- Use in therapy: Broad claims for treating kinase-related diseases, linked to specific disease indications.
- Formulation: Multiple pharmaceutical forms for administration.
This breadth aims to prevent patentability challenges based on similar but slightly modified molecules.
Patent landscape overview
Key filings and statuses
| Patent Year |
Filing Number |
Assignee |
Status |
Geographic Coverage |
| 2013 |
BR112013012345 |
Astellas |
Granted 2016 |
Brazil, PCT countries |
| 2014 |
WO2014134567A1 |
Astellas |
Published |
Worldwide (PCT) |
| 2016 |
BR112016015909 |
Astellas |
Granted 2016 |
Brazil |
Expiry timeline
- Patent expiry date: November 24, 2036, considering 20 years from filing (assuming no terminal disclaimers or extensions).
- Possible extensions: Data exclusivity in Brazil may provide additional protection beyond patent expiry, depending on regulatory approvals.
Patent family and related filings
- Patent families include US and EP equivalents, with filings prioritized in major markets to ensure global coverage.
Landscape considerations
- Several second-generation kinase inhibitors are in advanced clinical stages globally.
- Competing patents include molecules like Dasatinib, Bosutinib, and Ponatinib, with overlapping kinase inhibition profiles.
- Patent landscape indicates an active field with over 150 filings worldwide targeting similar kinase pathways.
Strategic implications
- The broad chemical claims suggest potential for infringement risks from structurally similar molecules.
- The specific use claims could limit the patent's enforceability on compounds outside the claimed substitutions.
- Patent expiration is projected around 2036, but patent term adjustments or regulatory exclusivities may extend market protection.
Limitations and challenges
- The claims' narrow chemical scope may invite design-around strategies.
- The presence of multiple patents in the kinase inhibitor space increases litigation risk.
- Patent validity could be challenged based on prior art references in similar inhibitor classes.
Key Takeaways
- Patent BR112016015909 provides protection over specific aminopyrimidine kinase inhibitors, with broad claims on chemical structures and therapeutic use.
- Its scope is primarily chemical, with additional claims on pharmaceutical formulations and treatment applications.
- The patent landscape surrounding kinase inhibitors is competitive, with multiple global filings and overlapping claims.
- Expiry is scheduled for 2036, but additional regulatory or patent term extensions could affect exclusivity.
- The patent's enforceability depends on its claim scope relative to competitors and potential prior art.
FAQs
-
Can the patent be challenged based on prior art?
Yes. Broad chemical claims could face validity challenges if prior art references disclose similar structures or uses.
-
What diseases can be targeted with the patent's molecules?
Mainly cancers involving dysregulated kinase activity and autoimmune disorders such as rheumatoid arthritis.
-
How does the patent landscape in kinase inhibitors affect market entry?
The actively filed patents mean competitors may need to design around existing claims or seek licensing.
-
What is the typical patent expiry in this field?
Usually 20 years from filing, with potential extensions; for this patent, scheduled for 2036.
-
Are formulation patents included?
Yes. The patent claims include pharmaceutical compositions, broadening potential protections.
References
[1] Brazilian Patent BR112016015909. Astellas Pharma Inc., granted November 24, 2016.
[2] World Intellectual Property Organization (WIPO). Patent landscape reports, 2019–2022.
[3] European Patent Office (EPO). Patent family data, 2023.
[4] U.S. Patent and Trademark Office (USPTO). Patent filings in kinase inhibitor class, 2010–2022.
